TORONTO, Feb. 15, 2012 /CNW/ - Patheon (TSX: PTI) a global provider of
drug development and manufacturing services to the international
pharmaceutical industry announced today that Stuart Grant has been
appointed Patheon's Executive Vice President, Chief Financial Officer.
Mr. Grant comes to Patheon following an accomplished career with
increasing levels of responsibility in finance for several successful,
global public companies.
"I am very pleased that Stuart has agreed to join the Patheon team,"
stated Jim Mullen, Patheon's Chief Executive Officer. "He is a proven
leader and respected financial executive who will be a key player in
Patheon's transformation. I look forward to the many contributions he
will make as we continue to implement our strategy to provide superior
returns to our shareholders over time."
Mr. Grant is joining Patheon after serving as Senior Vice President and
Chief Financial Officer of BioCryst Pharmaceuticals, Inc., where he was
a key player in the creation and execution of a company-wide strategy
that stabilized, funded and enabled future operations of the company.
His responsibilities included the finance, information technology,
supply chain operations, manufacturing and communications functions.
Prior to joining BioCryst, Mr. Grant was Group Chief Financial Officer
for Serono SA where he worked for 12 years, three years in his last
position, until the company was acquired. Mr. Grant also spent 15
years in finance at Digital Equipment Company and several years working
as a tax consultant and senior auditor for Price Waterhouse in Glasgow,
Mr. Grant holds a Bachelor of Accountancy from the University of
Glasgow, Glasgow, Scotland and is a Chartered Accountant with the
Institute of Chartered Accountants of Scotland.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, soft gel, solid and liquid forms.
The company's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization.
The company's integrated development and manufacturing network of 10
manufacturing facilities, nine development centers and one clinical
trial material packaging facility across North America and Europe,
enables customer products to be launched with confidence anywhere in
SOURCE Patheon Inc.
For further information:
Investor Relations and Corporate Communications
Tel: (919) 226-3313